Shelf offering
Open the filing on sec.gov
Jaguar Health, Inc. (JAGX)
Nasdaq: JAGX · Pharmaceutical Preparations · San Francisco, CA · filing with the SEC since 2013
The companyfiscal 2025, as filed
Revenue$11.5M-1.5%
Net income-$53.6M-39.2%
Earnings per share$-22.97+82.4%
Operating cash flow-$23.7M+19.4%
Cash$968,000-87.9%
Debtn/a
Shareholders’ equity-$18.7M-387.8%
Shares, diluted2,332,401+691.9%
Return on equityn/a
The recordfrom its filings
Filings in 202687
Newest filingNov 9 · 424B5
Annual reportApr 7, 2026
Quarterly reportAug 19, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted17
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Revenue $27.8MCash from operations -$6.7Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Shelf offering
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Registration effective
Open the filing on sec.gov
Shelf registration, amended
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Extra proxy material
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Shelf registration
Open the filing on sec.gov
Proxy statement
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.